



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/755,996

01/13/2004

Peter M. Bonutti

780-A03-021-5

1472

33771

7590

07/07/2006

PAUL D. BIANCO: FLEIT, KAIN, GIBBONS,
GUTMAN, BONGINI, & BIANCO P.L.
21355 EAST DIXIE HIGHWAY
SUITE 115
MIAMI, FL 33180

EXAMINER

HOFFMAN, MARY C

ART UNIT

PAPER NUMBER

3733

DATE MAILED: 07/07/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No. 10/755,996	Applicant(s) BONUTTI, PETER M.	
	Examiner Mary Hoffman	Art Unit 3733	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 25 April 2006.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1,4-10,13-15 and 19-23 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1,4-10,13-15 and 19-23 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☒ The specification is objected to by the Examiner.
- 10) ☒ The drawing(s) filed on 1/13/2004 is/are: a) ☒ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|---|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| Paper No(s)/Mail Date. _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Continued Examination Under 37 CFR 1.114

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 4/25/2006 has been entered.

Specification

Applicant is reminded of the proper language and format for an abstract of the disclosure.

The abstract should be in narrative form and generally limited to a single paragraph on a separate sheet within the range of 50 to 150 words. It is important that the abstract not exceed 150 words in length since the space provided for the abstract on the computer tape used by the printer is limited. The form and legal phraseology often used in patent claims, such as "means" and "said," should be avoided. The abstract should describe the disclosure sufficiently to assist readers in deciding whether there is a need for consulting the full patent text for details.

The language should be clear and concise and should not repeat information given in the title. It should avoid using phrases which can be implied, such as, "The disclosure concerns," "The disclosure defined by this invention," "The disclosure describes," etc.

The abstract of the disclosure is objected to because it is over the 150 word limit.

Correction is required. See MPEP § 608.01(b).

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 1, 8-9, 13-15, 19-23 are rejected under 35 U.S.C. 103(a) as being unpatentable over Stone (U.S. Patent No. 6,008,433) in view of Michelson (U.S. Patent No. 5,609,635).

Stone discloses an implantable device for changing the spatial relationship between first and second bones comprising a body (see FIG. 2b), wherein the body includes bone-contacting first (top surface including connected tab portion surface) and second major surfaces (bottom surface including connected tab portion surface), and a side surface (back facing surface of tab portion) there between and wherein one major surface tapers to form a pointed edge with the other major surface (see right edge surface of FIG. 2b). The body has an open cellular structure to provide cavities in which bone can grow through (col. 6, lines 34-36). The body is made of a biocompatible metallic material (col. 6, lines 44-46). At least some of the cavities contain a bone growth promoting material (col. 7, lines 8-14). A portion of the side surface has a configuration corresponding to at least a section of an outer side surface of one of the first and second bones. The body includes a first channel (see screw hole in FIG. 2b) extending through the first major surface and side surface. The device includes first and second fastener means disposed through the first and second channels, respectively.

Art Unit: 3733

There are channels on the top surface and bottom surface in which the first and second fastener are disposed, respectively. The fastener means are screws (ref. #172).

Stone discloses the claim invention except for the device being coated with a bone growth promoting material, wherein the bone growth promoting material includes a bone morphogenic protein.

Michelson discloses using a coating of bone growth promoting material, wherein the bone growth promoting material includes a bone morphogenic protein, in order to promote bioactive fusion (col. 9, lines 20-24).

It would have been obvious to one of ordinary skill in the art at the time the invention was made to construct the device of Stone with the coating of Michelson in order to promote bioactive fusion.

Claims 4-7 are rejected under 35 U.S.C. 103(a) as being unpatentable over Stone (U.S. Patent No. 6,008,433) in view of Michelson (U.S. Patent No. 5,609,635), and further in view of Jefferies (U.S. Patent No. 4,394,370).

Stone in view of Michelson discloses the claimed invention except for the coating being apatite compositions such as demineralized bone powder and collagen.

Jefferies teaches both demineralized bone powder and collagen as materials to induce the formation of osseous tissue (Abstract).

It would have been obvious to one of ordinary skill in the art at the time the invention was made to have the coating of the Stone in view of Michelson include demineralized bone powder and collagen in view of Jeffries, since those materials are

Art Unit: 3733

well-known in the art of bone fusion as materials to induce the formation of osseous tissue.

Claim 10 is rejected under 35 U.S.C. 103(a) as being unpatentable over Stone (U.S. Patent No. 6,008,433) in view of Michelson (U.S. Patent No. 5,609,635), and further in view of Zdeblick et al. (U.S. Patent No. 5,669,909).

Stone in view of Michelson discloses open cellular and biocompatible material, including metals, but does not specifically disclose tantalum.

Zdeblick et al. teaches using porous tantalum in implants to allow bone ingrowth.

It would have been obvious to one of ordinary skill in the art at the time the invention was made to construct the device of Stone in view of Michelson using tantalum in view of Zdeblick et al. to allow bone ingrowth.


Conclusion


Any inquiry concerning this communication or earlier communications from the examiner should be directed to Mary Hoffman whose telephone number is 571-272-5566. The examiner can normally be reached on Monday-Friday 9:00-5:00pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Eduardo C. Robert can be reached on 571-272-4719. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 3733

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

MC



CORRINE McDERMOTT
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 3700